PCPalle Mark Christensen

Palle Mark Christensen

*This is an algorithmically generated author record based on publicly available information.

Palle Mark Christensen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations between patients’ risk attitude and their adherence to statin treatment – a population based questionnaire and register study

    by Benedicte Lind Barfoed, Maja Skov Paulsen, Palle Mark Christensen, Peder Andreas Halvorsen, Trine Kjær, Mogens Lytken Larsen, Pia Veldt Larsen, Jesper Bo Nielsen, Jens Søndergaard, Dorte Ejg Jarbøl

    Poor adherence to medical treatment may have considerable consequences for the patients’ health and for healthcare costs to society. The need to understand the determinants for poor adherence has motivated several studies on socio-demographics and comorbidity. Few studies focus on the association between risk attitude and adherence. The aim of the present study was to estimate associations between patients’ adherence to statin treatment and different dimensions of risk attitude, and to identify subgroups of patients with poor adherence. Population-based questionnaire and register-based study on a sample of 6393 persons of the general. Danish population aged 20–79. Data on risk attitude were based on 4 items uncovering health-related as well as financial dimensions of risk attitude. They were collected through a web-based questionnaire and combined with register data on redeemed statin prescriptions, sociodemographics and comorbidity. Adherence was estimated by proportion of days covered using a cut-off point at 80 %. For the dimension of health-related risk attitude, “Preference for GP visit when having symptoms”, risk-neutral and risk-seeking patients had poorer adherence than the risk-averse patients, OR 0.80 (95 %-CI 0.68–0.95) and OR 0.83 (95 %-CI 0.71–0.98), respectively. No significant association was found between adherence and financial risk attitude. Further, patients in the youngest age group and patients with no CVD were less adherent to statin treatment. We find some indication that risk attitude is associated with adherence to statin treatment, and that risk-neutral and risk-seeking patients may have poorer adherence than risk-averse patients. This is important for clinicians to consider when discussing optimal treatment decisions with their patients. The identified subgroups with the poorest adherence may deserve special attention from their GP regarding statin treatment.


  • Number‐Needed‐to‐Treat (NNT) – Needs Treatment with Care

    by Palle Mark Christensen, Ivar Sønbø Kristiansen

    The “number‐needed‐to‐treat” (NNT) was introduced about 15 years ago and has gained widespread use. It has been claimed to be “easy to understand” and gives “intuitive meaning”. When used to measure the effectiveness of interventions targeting chronic disease processes e.g. atherosclerosis and osteoporosis, NNT (as well as relative and absolute risk reduction) does not capture the crucial time component, a fact that has important consequences: NNT varies over time, it may not mean that adverse events (fractures, myocardial infarctions etc.) are avoided, but simply that they are postponed. Finally, empirical studies indicate that lay people and doctors misunderstand NNT. We recommend that NNT be used with considerable care. There is probably no single effect measure that is able to convey all necessary information.


  • Open Access

    Cost-Effectiveness of Alendronate in the Prevention of Osteoporotic Fractures in Danish Women

    by Palle Mark Christensen, Kim Brixen, Dorte Gyrd-Hansen, Ivar Sonbo Kristiansen

    Pharmacological interventions for osteoporosis may reduce morbidity and mortality, but they incur additional health care costs. The aim was to quantify the additional costs and health benefits of prescribing alendronate 10 mg and calcium/vitamin D daily for 71-year-old women with a fracture risk twice that of the population average in stead of calcium/vitamin D alone. A state transition model based primarily on Scandinavian data was developed. Women were followed from age of 71 years until 100. Alendronate was assumed to reduce the fracture risk by 50%. Health benefits from the interventions were expressed in terms of life years, quality adjusted life years, and fractures avoided. Societal costs were estimated using literature estimates and Danish tariffs. All costs were measured in 2002 Danish Kroner (DKK). Future costs and benefits were discounted at 5% per year. The incremental cost per QALY gained was DKK125,000 while the cost per life year gained was DKK 374,000. The use of alendronate was cost-saving when 1) the treatment was extended to five years, 2) the risk of fracture was four times the population average, 3) the effect of alendronate was assumed to persist for three years after discontinuation of treatment, 4) a greater proportion had severe sequelae after a hip fracture, or 5) the start of therapy was delayed until age of 77 years. In conclusion, the use of alendronate compares well with other well established therapies in terms of cost-effectiveness in older women with high risk of fracture.


    • 28 February 2005
      • Vol. 167  (9) , 1031-3

    [Evaluation of the effects of treatment of osteoporosis].

    by Palle Mark Christensen, Henrik Ancher Sørensen, Peter Vestergaard

    • 5 January 2004
      • Vol. 166, 49-53

    [Compliance with the treatment of osteoporosis with diphosphonates. A questionnaire among postmenopausal women].

    by Rasmus Wulff, Bo Abrahamsen, Charlotte Albjerg Ejersted, Palle Mark Christensen, Kim T Brixen

    • 4 March 2002
      • Vol. 164  (10) , 1339-45

    [Pharmaco-economic evaluation of drug therapy osteoporosis. A literature review].

    by Palle Mark Christensen, Kim Brøsen, Kim T Brixen, Henning Beck-Nielsen, Jes Søgaard, Ivar Sønbø Kristiansen

    Interventions against osteoporosis may reduce the incidence of fractures in patients and costs to society, but they also incur additional expenditure and thus call for economic evaluation. The aim of this paper was to evaluate existing literature by applying cost-effectiveness (CEA) and cost-utility analyses (CUA) to pharmacological treatment of osteoporosis. MEDLINE and the reference lists of relevant papers were searched to identify original papers on the subject. Studies were included if they were peer reviewed, written in English or a Scandinavian language, and reported CEA or CUA for a specified pharmacological intervention. Of the 37 identified studies, 16 met the inclusion criteria (ten CUA and six CEA), and 21 studies were excluded. Of the studies examined, 13 studies concerned hormone replacement therapy (HRT), four bisphosphonate, four calcitonin, and four calcium supplementation and/or vitamin D treatment. All were based on simulations of the long-term effects of the intervention with respect to cost and effect. However, the studies varied widely in patient selection and assumptions about duration and effectiveness of intervention, assessment of quality of life, and mortality following hip fracture. The published studies rely on limited empirical data as regards the effect of treatment, costs, and adverse effects. Several, however, indicate that some interventions may be cost-effective in high-risk groups.